CD302 and acute myeloid leukemia: The geoMFI ratio of CD302 staining relative to a mouse IgG1 isotype control demonstrated that CD302 was expressed 3-fold higher than background on the surface of AML blasts in 88% of patients (29/33) and in LSC enriched CD34+CD38- cells in 80% of patients (16/20; Fig 1B).